MedPath

Yoga for patients with Implantable Cardiac Devices

Phase 2
Not yet recruiting
Conditions
Patients implanted with Implantable Cardioverter Defibrillator (ICD)
Registration Number
CTRI/2018/08/015397
Lead Sponsor
MINISTRY OF AYUSH
Brief Summary

Ventricular arrhythmias are an important cause of morbidity, mortality and sudden death. There is a direct co-relationship between burden of ventricular arrhythmias and total mortality. Autonomic tone plays a central role in occurrence of ventricular arrhythmias with Yoga having a profound influence on cardiovascular physiology through its effects on central neural outflow and autonomic tone. It also improves mental and psychological wellbeing through central effects on mood and emotion.  This is a prospective, randomized, controlled study designed to test the effects of yoga on psychological and arrhythmic outcomes in patients with structural heart disease. Patients with structural heart disease who have an implantable cardioverter defibrillator or a cardiac resynchronization device with defibrillator will be randomized to either Yoga Intervention (with usual care) or usual care. Patients will have periodic assessment of clinical characteristics, arrhythmia burden, psychological and quality of life parameters at baseline, 12 weeks and at end of study.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

1.Patients between 18to 60 years of age 2.ICD implanted at least 8 weeks prior 3.Willing to participate in Yoga 4.NYHA Class I or II symptoms 5.Deemed ready to participate by their physician.

Exclusion Criteria

1.Contraindications to Yoga 2.Advanced heart failure (NYHA Class III/IV) 3.Pregnancy 4.Patients already practicing regular Yoga or receiving any other alternative medicine for the same desired effect.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.ICDs/ CRT-Ds burden of ventricular arrhythmia will be assessed from device interrogation.Data collection will be done at baseline, 12 weeks & 6 months in person at the hospital.
2.Florida Shock Anxiety Scale (FSAS) will be used to access the shock anxietyData collection will be done at baseline, 12 weeks & 6 months in person at the hospital.
3.Zung self-assessment anxiety score (SAS)Data collection will be done at baseline, 12 weeks & 6 months in person at the hospital.
4.Zung self-assessment depression score (SDS)Data collection will be done at baseline, 12 weeks & 6 months in person at the hospital.
5.Quality of Life outcomes will be measured using the WHO QoL BREF questionnaire.Data collection will be done at baseline, 12 weeks & 6 months in person at the hospital.
Secondary Outcome Measures
NameTimeMethod
1.Florida Patient Acceptance Survey (FPAS) will be used to access the acceptance of the ICD device by the patient2.Mental stress will be assessed using the Perceived Stress Scale (PSS)

Trial Locations

Locations (1)

ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHI

🇮🇳

Delhi, DELHI, India

ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHI
🇮🇳Delhi, DELHI, India
Dr Nitish Naik
Principal investigator
01126593218
nitishnaik@yahoo.co.in

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.